45 results
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
revenue recorded under the Roche License and Collaboration agreement.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 … )
(unaudited)
Three months ended
March 31,
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
share and per share amounts)
Three months ended
December 31,
Year ended
December 31,
Operating expenses:
Research and development
General … also plans to present at an educational session at AACR on molecular glue degraders.
FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Research
8-K
EX-99.1
xdk8o
9 Nov 23
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
7:27am
424B5
438i483
26 Oct 23
Prospectus supplement for primary offering
4:55pm
8-K
EX-99.1
k3018dmm7cxm4stiv2
10 Aug 23
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:19am
8-K
EX-99.1
9nl04eie
11 May 23
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
7:34am
PRE 14A
capponp
12 Apr 23
Preliminary proxy
4:07pm
8-K
EX-99.1
oa3eu v2ztm39bdyn0yd
10 Nov 22
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
7:36am
8-K
EX-99.1
r8kf5jpnwaym 99
11 Aug 22
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
7:35am
S-3
mgs7pnt
1 Jul 22
Shelf registration
5:01pm